<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03941769</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0674</org_study_id>
    <secondary_id>NCI-2019-02124</secondary_id>
    <secondary_id>2018-0674</secondary_id>
    <secondary_id>R01CA061508</secondary_id>
    <nct_id>NCT03941769</nct_id>
  </id_info>
  <brief_title>Recombinant Human Interleukin-7 to Promote T-Cell Recovery After Cord Blood Transplant</brief_title>
  <official_title>A Phase I Study of Recombinant Human Interleukin-7 to Promote T-Cell Recovery After Cord Blood Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies side effects and best dose of recombinant interleukin-7 in&#xD;
      promoting immune cell recovery in patients with acute myeloid leukemia, myelodysplastic&#xD;
      syndrome, chronic myeloid leukemia, or myeloproliferative disease after a cord blood&#xD;
      transplant. Umbilical cord blood is a source of blood-forming cells that can be used for&#xD;
      transplant, also known as a graft. However, there is a small number of blood-forming cells&#xD;
      available in the transplant, which may delay the &quot;take&quot; of the graft in the recipient.&#xD;
      Recombinant interleukin-7 may affect the &quot;take&quot; of the graft and the recovery of certain&#xD;
      blood cells related to the immune system (called T-cells, natural killer cells, and B cells)&#xD;
      in patients who have had a cord blood transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety and establish the maximum tolerated dose (MTD) and dose limiting&#xD;
      toxicities (DLT) of recombinant interleukin-7 (interleukin 7 [IL-7, CYT107]).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the rate of cytomegalovirus (CMV), Epstein-Barr virus (EBV) and BK viral&#xD;
      infections in cord blood transplant (CBT) patients who receive three doses of IL-7 following&#xD;
      engraftment.&#xD;
&#xD;
      II. To calculate the overall survival (OS), progression-free survival (PFS), and cumulative&#xD;
      incidence of graft versus host disease (GVHD) and cumulative incidence of relapse.&#xD;
&#xD;
      III. To evaluate the effects of CYT107 on the recovery of T, natural killer (NK) and B cell&#xD;
      populations and their functions in vitro; these data will be used to identify the optimal&#xD;
      dose to move to a phase II trial.&#xD;
&#xD;
      IV. To obtain information about the pharmacokinetic (PK) profile of CYT107 by estimating time&#xD;
      to maximum concentration (Tmax), concentration maximum (Cmax), half-life, clearance and&#xD;
      area-under-the-curve (AUC).&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Within 60-180 days after CBT, patients receive recombinant interleukin-7 intramuscularly (IM)&#xD;
      or subcutaneously (SC) once per week for 3 weeks.&#xD;
&#xD;
      After completion of study treatment, patients are followed for up to 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicity</measure>
    <time_frame>Up to 42 days after first injection</time_frame>
    <description>Will be defined as any of the events: grade 3 or 4 graft versus host disease (GVHD), secondary graft failure, disease relapse, development of post-transplant lymphoproliferative disorder, development of progressive multifocal leukoencephalopathy or grade 3-4 organ failure attributable to recombinant human interleukin-7 (CYT107) and death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>Up to 42 days after first injection</time_frame>
    <description>Bayesian model averaging-continual reassessment method will be applied to determine an optimal recommended dose of CYT107.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of viral infections</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will determine the rate of cytomegalovirus, Epstein-Barr virus, and BK viral infections in cord blood transplant patients who receive three doses of CYT107 following engraftment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be estimated using the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 12 months from the start of therapy</time_frame>
    <description>Will be estimated using the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of GVHD</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T, natural killer (NK), and B cell populations</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Effects of CYT107 on the recovery of T, NK, and B cell populations and their functions in vitro will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CYT107 blood levels</measure>
    <time_frame>Prior to first CYT107 injection and 1, 3, 5, 7, 9, and 24 hours after first injection</time_frame>
    <description>CYT107 blood levels will be submitted to a Model-independent pharmacokinetic analysis allowing to estimate time to maximum concentration, concentration maximum, half-life, clearance and area-under-the-curve.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Cord Blood Transplant Recipient</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <arm_group>
    <arm_group_label>Supportive care (recombinant interleukin-7)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within 60-180 days after CBT, patients receive recombinant interleukin-7 IM or SC once per week for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Interleukin-7</intervention_name>
    <description>Given IM or SC</description>
    <arm_group_label>Supportive care (recombinant interleukin-7)</arm_group_label>
    <other_name>CYT 99 007</other_name>
    <other_name>CYT-107</other_name>
    <other_name>IL-7</other_name>
    <other_name>Lymphopoietin-1</other_name>
    <other_name>Recombinant Human Interleukin-7</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient post a cord blood transplant (CBT) with documented absolute neutrophil&#xD;
             engraftment and no evidence of GVHD or no history of acute or chronic GVHD requiring&#xD;
             systemic steroids&#xD;
&#xD;
          -  Patients with documented engraftment but require granulocyte-colony stimulating factor&#xD;
             (G-CSF) to treat myelosuppression induced by drugs used to treat or prevent infection&#xD;
             are eligible&#xD;
&#xD;
          -  Karnofsky performance status (KPS) &gt; 60%&#xD;
&#xD;
          -  Absence of dyspnea or hypoxia (&lt; 90% of saturation by pulse oximetry on room air)&#xD;
&#xD;
          -  Bilirubin =&lt; 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])&#xD;
             and/or alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 2.5 x ULN&#xD;
&#xD;
          -  Prothrombin time (PT)/partial prothrombin time (PTT) &lt; 1.5 x ULN&#xD;
&#xD;
          -  Calculated creatinine clearance &gt; 60 mL/min/1.73 m^2&#xD;
&#xD;
          -  Diagnosis of acute myeloid leukemia; myelodysplastic syndrome; chronic myeloid&#xD;
             leukemia or myeloproliferative disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  History of lymphoid malignancy (including Hodgkin disease, non-Hodgkin lymphoma, acute&#xD;
             lymphoblastic leukemia and chronic lymphocytic leukemia) or acute biphenotypic&#xD;
             leukemia&#xD;
&#xD;
          -  History of Epstein-Barr virus (EBV) associated lymphoproliferation&#xD;
&#xD;
          -  Active uncontrolled viral, bacterial or fungal infection&#xD;
&#xD;
          -  Documented human immunodeficiency virus (HIV)-1 or -2, hepatitis B virus (HBV), or&#xD;
             hepatitis C virus (HCV) infection at any time before or after transplant. (A positive&#xD;
             hepatitis B serology indicative of a previous immunization is not an exclusion&#xD;
             criteria)&#xD;
&#xD;
          -  EBV viremia equal to or greater than 500 copies EBV deoxyribonucleic acid (DNA)/mL of&#xD;
             blood by quantitative polymerase chain reaction (PCR)&#xD;
&#xD;
          -  Positive cytomegalovirus (CMV) antigenemia&#xD;
&#xD;
          -  History of autoimmune disease&#xD;
&#xD;
          -  Receiving systemic corticosteroid therapy&#xD;
&#xD;
          -  Receiving concurrent treatment with another investigational drug and/or biological&#xD;
             agent&#xD;
&#xD;
          -  Receiving anticoagulant therapy&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Corrected QT (QTc) prolongation (QTc &gt; 470 ms) or prior history of significant&#xD;
             arrhythmia or electrocardiogram (ECG) abnormalities&#xD;
&#xD;
          -  Active drug or alcohol use or dependence that, in the opinion of the investigator,&#xD;
             would interfere with adherence to study requirements&#xD;
&#xD;
          -  Any past or current psychiatric illness that, in the opinion of the investigator,&#xD;
             would interfere with adherence to study requirements or the ability and willingness to&#xD;
             give written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gheath Al-Atrash</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gheath Al-Atrash</last_name>
    <phone>713-563-3324</phone>
    <email>galatras@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Marin</last_name>
      <phone>713-792-8750</phone>
    </contact>
    <investigator>
      <last_name>David Marin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

